Press releases

Warsaw, 9 June 2016


BIOTON S.A. and MSD, a part of the American concern Merck & Co., have concluded an agreement according to which BIOTON shall cooperate with MSD within the scope of development of the market of hypercholesterolemia treatment with an innovative medication - Ezetrol (ezetymib).

read more

Warsaw, 26 May 2016


On 25 May 2016 the Supervisory Board of Bioton S.A. ("Bioton", "Company") decided to form a strategy development committee whose principal task will be to raise Bioton's operations to global level and to develop diabetes products portfolio, as the main area of Company operation. Therefore, the Supervisory Board has decided to delegate its Chairman, Mr Jubo Liu and a Vice Chairman, Mr Dariusz Trzeciak, to directly supervise the process of development and implementation of the new strategy of the Company.

read more

Current reports

Warsaw, 20 July 2016

Current report 2016/36 dated 19.07.2016, time 18.25 UTC

Conclusion of a memorandum of understanding on termination of agreements with the BIOTEC OOO Group and conclusion of an agreement with the Pharmasyntez – Tyumen OOO Group on the sales of BIOTON S.A. insulins in the Russian Federation.

read more

Warsaw, 19 July 2016

Current report 2016/35 dated 18.07.2016

Notification by Bimeda Holding Ltd of the resignation from the intention to increase the share in BIOTON S.A.

read more